Payment overview · 2025
General Payments
$85.65
4 reported records · 2 companies
Healthcare provider profile · identity verified
Lewis Barwick, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TAMPA, FL · NPI 1689332892
Verified facts
What the public records show
CMS Open Payments records show Lewis Barwick, APRN received $85.65 in general payments during 2025 across 4 reported records.
Gilead Sciences, Inc. accounted for 74.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Descovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $63.94 | 74.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.71 | 25.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.65 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 734 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 64 |
| Gabapentin | Gabapentin | 412 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 48 |
| Metformin Hcl | Metformin Hcl | 340 | 47 |
| Losartan Potassium | Losartan Potassium | 330 | 44 |
| Lisinopril | Lisinopril | 314 | 50 |
| Potassium Chloride | Potassium Chloride | 291 | 40 |
| Furosemide | Furosemide | 287 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 46 |
| Donepezil Hcl | Donepezil Hcl | 267 | 38 |
| Memantine Hcl | Memantine Hcl | 228 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 30 |
| Famotidine | Famotidine | 213 | 27 |
| Trazodone Hcl | Trazodone Hcl | 208 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 33 |
| Divalproex Sodium | Divalproex Sodium | 169 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 26 |
| Omeprazole | Omeprazole | 158 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 40 |
| Carvedilol | Carvedilol | 156 | 22 |
| Eliquis | Apixaban | 155 | 28 |
| Sertraline Hcl | Sertraline Hcl | 155 | 25 |
| Montelukast Sodium | Montelukast Sodium | 153 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 26 |
| Loperamide | Loperamide Hcl | 144 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 18 |
| Ibuprofen | Ibuprofen | 133 | 21 |
| Alprazolam | Alprazolam | 121 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 17 |
| Rybelsus | Semaglutide | 113 | 14 |
| Tramadol Hcl | Tramadol Hcl | 109 | 23 |
| Spironolactone | Spironolactone | 104 | 16 |
| Buspirone Hcl | Buspirone Hcl | 100 | 18 |
| Levetiracetam | Levetiracetam | 100 | 15 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 97 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 31 |
| Celecoxib | Celecoxib | 86 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 16 |
| Ezetimibe | Ezetimibe | 74 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 18 |
| Lactulose | Lactulose | 73 | 15 |
| Descovy | Emtricitabine/Tenofov Alafenam | 72 | 12 |
| Ammonium Lactate | Ammonium Lactate | 68 | 16 |
| Risperidone | Risperidone | 68 | 15 |
| Simvastatin | Simvastatin | 68 | 11 |
| Nifedipine Er | Nifedipine | 65 | suppressed |
| Cilostazol | Cilostazol | 64 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 21 |
| Vascepa | Icosapent Ethyl | 62 | suppressed |
| Desloratadine | Desloratadine | 58 | 12 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 39 |
| Ozempic | Semaglutide | 57 | suppressed |
| Nystatin | Nystatin | 56 | 14 |
| Temazepam | Temazepam | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Gemtesa | Vibegron | 52 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 13 |
| Finasteride | Finasteride | 48 | suppressed |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 38 |
| Nitroglycerin | Nitroglycerin | 46 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Prednisone | Prednisone | 42 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Cyclosporine | Cyclosporine | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 23 |
| Digoxin | Digoxin | 34 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 15 |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | suppressed |
| Lumigan | Bimatoprost | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | 11 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Valproic Acid | Valproic Acid | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Nabumetone | Nabumetone | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 21 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Linzess | Linaclotide | 17 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 12 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.65 · 4 records | Gilead Sciences, Inc. | NURTEC ODT, PAXLOVID | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error